Advertisement
Essay

Challenging Medical Ghostwriting in US Courts

  • Xavier Bosch mail,

    xavbosch@clinic.ub.es

    Affiliation: Department of Internal Medicine at the Hospital Clínic and the Institut d'Investigacions Biomèdiques August Pí i Sunyer, University of Barcelona, Barcelona, Spain

    X
  • Bijan Esfandiari,

    Affiliation: Law Firm of Baum, Hedlund, Aristei & Goldman, Los Angeles, California, United States of America

    X
  • Leemon McHenry

    Affiliation: Department of Philosophy, California State University, Northridge, California, United States of America

    X
  • Published: January 24, 2012
  • DOI: 10.1371/journal.pmed.1001163
  • Published in PLOS Medicine

About the Authors

Xavier Bosch
Department of Internal Medicine at the Hospital Clínic and the Institut d'Investigacions Biomèdiques August Pí i Sunyer, University of Barcelona, Barcelona, Spain
Bijan Esfandiari
Law Firm of Baum, Hedlund, Aristei & Goldman, Los Angeles, California, United States of America
Leemon McHenry
Department of Philosophy, California State University, Northridge, California, United States of America

Corresponding Author

Email: xavbosch@clinic.ub.es

Competing Interests

BE has participated as an attorney in litigation involving Prozac, Paxil, and Avandia and other pharmaceutical products. LM is a member of Healthy Skepticism and research consultant for the law firm of Baum, Hedlund, Aristei & Goldman, Los Angeles, California. He has participated in litigation involving Prozac, Zoloft, Paxil, Avandia, and other pharmaceutical products. All other authors have declared that no competing interests exist.

Author Contributions

Conceived and designed the experiments: XB BE LM. Analyzed the data: XB BE LM. Wrote the first draft of the manuscript: XB BE LM. Contributed to the writing of the manuscript: XB BE LM. ICMJE criteria for authorship read and met: XB BE LM. Agree with manuscript results and conclusions: XB BE LM. Jointly developed the structure and arguments of the paper: XB BE LM. Made critical revisions and approved final version: XB BE LM.